ArticleCardio-oncology (London, England)2026
Cardiovascular risk after cancer in patients with ischemic heart disease or peripheral artery disease.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with ischemic heart disease (IHD) or peripheral artery disease (PAD) represent a high-risk cardiovascular phenotype. When cancer is diagnosed in this population, clinical attention may shift toward treatment of the malignancy, potentially leading to under-recognition of pre-existing cardiovascular disease and its associated risks. Real-world data describing early cardiovascular outcomes after cancer diagnosis in this subgroup are however limited. The objective was to describe 1-year risks of cardiovascular death, major adverse cardiovascular events (MACE: ischemic stroke, systemic embolism, myocardial infarction, and hemorrhagic stroke), and venous thromboembolism (VTE: pulmonary embolism, and deep vein thromboembolism) after cancer diagnosis and to compare these risks across cancer sites within this high-risk vascular population.
methodsUsing nationwide Danish registries, we identified 91,253 patients with IHD and/or PAD who developed a first primary cancer between 2002 and 2022. One-year cumulative incidences of cardiovascular death, MACE, and VTE were estimated using competing-risk methods. Multivariable Cox regression models were used to identify clinical predictors of cardiovascular outcomes.
resultsWithin one year of cancer diagnosis, 33% of patients died. The cumulative incidence of cardiovascular death was 2.4%, MACE 2.8%, and VTE 1.8%, with substantial variation across cancer types. Neurologic, respiratory, and digestive tract cancers were associated with the highest cardiovascular risk. Prior cardiovascular comorbidity strongly predicted adverse outcomes. Statin therapy was associated with lower cardiovascular mortality (hazard ratio [HR] 0.66) and fewer MACE events (HR 0.84).
conclusionsCancer patients with pre-existing IHD or PAD experience a high burden of early cardiovascular and thrombotic events with marked variation across cancer types. These findings underscore the need for integrated cardio-oncology care and support continued use of guideline-directed cardiovascular preventive therapies during cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.